arrow
Back
D

David I. Quinn

AbbVie Inc.

77H-index
829Paper Count
2.8WCitation Count
Published Papers 173
Publication Date
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis
err2026-03-19
err0
errOAAI
errJohn Mascarenhas; Laura Fogliatto; Steven Green; Ignacio Corvalan; Elie Traer; Keita Kirito; Hun Chuah; Kazuki Sakatoku; Rasmus Hoeg; Mohamad Khawandanah; David Lavie; Zoë Hunter; David Quinn; Yizhuo Wang; Jason Harb; Jiuhong Zha; Uriel Malyankar; Ellen Ritchie
errShare
errSave
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer
err2025-11-29
err0
errOAAI
errStuthi Perimbeti; Anmbreen Jamroze; Dharmesh Gopalakrishnan; Rohit Jain; Changchuan Jiang; Julianne L. Holleran; Robert A. Parise; Robert Bies; David Quinn; Kristopher Attwood; Xiaozhuo Liu; Kelly Green; Jason S. Kirk; Jan H. Beumer; Dean G. Tang; Gurkamal Chatta
errShare
errSave
Efficacy of neratinib-based therapy in ERBB2-mutant lung adenocarcinomas: findings from 2 international phase 2 studies
err2025-10-01
err0
PREAI
errBob T. Li; Leena Gandhi; Vignesh Ravichandran; Benjamin Besse; Julien Mazières; Geoffrey I. Shapiro; Valentina Boni; Saiama N. Waqar; Haeseong Park; David I. Quinn; Alejandro Martinez; Salomon M. Stemmer; Alexis B. Cortot; Fabrice Barlesi; Elisabeth Quoix; Mark E. Burkard; S. Duygu Selcuklu; Casey Hunt; Mark T.A. Donoghue; Mark G. Kris; Judith Bebchuk; Lisa D. Eli; Leanne McCulloch; David B. Solit; Pasi A. Jänne
errShare
errSave
Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer
errCANCERS
IF4.4
err2025-05-21
err0
errOAAI
errZang, Peter D.; Da Silva, Diane M.; Liu, Zhang-Xu; Kandukuri, Shivani; Tsao-Wei, Denice; D'Souza, Anishka; Kast, W. Martin; Pal, Sumanta K.; Kefauver, Cheryl; Juanqueira, Maribel; Yang, Lixin; Quinn, David I.; Dorff, Tanya B.
errShare
errSave
Anthracycline-induced arterial toxicity: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography
err2024-10-28
err0
PREAI
errRankin, S.; Fontain, C.; Gemmell, A.; Quinn, D.; Henderson, A.; Mcclure, J.; Small, S.; Venugopal, B.; Mckay, P.; Slomka, P.; Colville, D.; Petrie, M. C.; Melendez, G. C.; Lang, N. N.
errShare
errSave
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
err2024-10-01
err2
errOAAI
errParikh, Mamta; Tangen, Catherine; Hussain, Maha H. A.; Gupta, Shilpa; Callis, Sam; Jo, Yeonjung; Harzstark, Andrea; Paller, Channing J.; George, Saby; Zibelman, Matthew R.; Cheng, Heather H.; Maughan, Benjamin L.; Zhang, Jingsong; Pachynski, Russell K.; Bryce, Alan H.; Lin, Daniel W.; Quinn, David I.; Lerner, Seth P.; Thompson, Ian M.; Dorff, Tanya B.; Lara, Primo N.; Agarwal, Neeraj
errShare
errSave
First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
err2024-09-01
err0
PREAI
errBerger, R.; Tolcher, A. W.; Dorff, T. B.; Okubo, S.; Abraham, L. S.; Reilly, R.; Stevenson, C.; Wang, S.; Arnold, J.; Mudd, S. R.; Alaei, S.; Hong, J.; Quinn, D. I.; Saad, F.; Powderly, J.
errShare
errSave
Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
err2024-09-01
err0
PREAI
errIngles, S. A.; Pinski, J.; Manojlovic, Z.; Xiong, S.; Weisenberger, D.; Goldkorn, A.; Tangen, C.; McConkey, D.; Lara, P. N.; Hussain, M.; Quinn, D. I.; Thompson, I. M.; Lerner, S.; Dorff, T. B.; Agarwal, N.
errShare
errSave
Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
err2024-09-01
err0
PREAI
errSadeghi, S.; Parikh, R.; Appleman, L. J.; Tsao-Wei, D.; Groshen, S.; Li, M.; Tagawa, S. T.; Nanus, D. M.; Molina, A. M.; Ornstein, M. C.; Rini, B. I.; Dreicer, R.; Quinn, D. I.; Lara, P. N.
errShare
errSave
A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
err2024-09-01
err0
PREAI
errD'Souza, A. A.; Mar, N.; Parikh, R.; Parikh, M.; Arora, M.; Hinton, S.; Lyou, Y. M.; Ohr, J.; Peracha, S.; Sadeghi, S.; Sulecki, M.; Thomas, R. A.; Villalona-Calero, M.; Lara, P. N.; Sharon, E.; Krailo, M.; Quinn, D. I.
errShare
errSave
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
err2024-08-22
err0
PREAI
errRonald de Wit; David J. Vaughn; Yves Fradet; Lawrence Fong; Miguel A. Climent; Andrea Necchi; Daniel P. Petrylak; Winald R. Gerritsen; Howard Gurney; David I. Quinn; Stéphane Culine; Cora N. Sternberg; Dean F. Bajorin; Toni K. Choueiri; Jin Xu; Kentaro Imai; Blanca Homet Moreno; Joaquim Bellmunt; Jae-Lyun Lee
errShare
errSave
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel
err2024-02-29
err0
PREAI
errLara Jr, Primo N.; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I.; LeBlanc, Michael; Thompson, Ian; Agarwal, Neeraj
errShare
errSave
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
err2024-02-01
err6
errOAAI
errLara, Primo N.; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I.; Leblanc, Michael; Vogelzang, Nicholas J.; Thompson, Ian; Agarwal, Neeraj
errShare
errSave
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
err2024-01-01
err8
errOAAI
errGrimm, Marc-Oliver; Oya, Mototsugu; Choueiri, Toni K.; Motzer, Robert J.; Schmidinger, Manuela; Quinn, David I.; Gravis-Mescam, Gwenaelle; Verzoni, Elena; Van den Eertwegh, Alfonsus J. M.; di Pietro, Alessandra; Mariani, Mariangela; Wang, Jing; Thomaidou, Despina; Albiges, Laurence
errShare
errSave
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
err2023-11-03
err0
errOAAI
errOh, Do-Youn; Maqueda, Maria Alsina; Quinn, David I.; O'Dwyer, Peter J.; Chau, Ian; Kim, Sun Young; Duran, Ignacio; Castellano, Daniel; Berlin, Jordan; Mellado, Begona; Williamson, Stephen K.; Lee, Keun-Wook; Marti, Francisca; Mathew, Paul; Saif, Muhammad Wasif; Wang, Ding; Chong, Elizabeth; Hilger-Rolfe, Jacqueline; Dean, James P.; Arkenau, Hendrik-Tobias
errShare
errSave
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314
err2023-10-01
err16
PREAI
errLu, Yi-Tsung; Plets, Melissa; Morrison, Gareth; Cunha, Alexander T.; Cen, Steven Y.; Rhie, Suhn K.; Siegmund, Kimberly D.; Daneshmand, Siamak; Quinn, David I.; Meeks, Joshua J.; Lerner, Seth P.; Petrylak, Daniel P.; Mcconkey, David; Flaig, Thomas W.; Thompson Jr, Ian M.; Goldkorn, Amir
errShare
errSave
SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer
err2023-09-11
err6
errOAAI
errZhou, Xinyi; Sekino, Yohei; Li, Hong-Tao; Fu, Guanghou; Yang, Zhi; Zhao, Shuqing; Gujar, Hemant; Zu, Xiongbing; Weisenberger, Daniel J.; Gill, Inderbir S.; Tulpule, Varsha; D'souza, Anishka; Quinn, David I.; Han, Bo; Liang, Gangning
errShare
errSave
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
err2023-02-06
err31
errOAAI
errHarding, James J.; Piha-Paul, Sarina A.; Shah, Ronak H. H.; Murphy, Jessica J.; Cleary, James M.; Shapiro, Geoffrey I.; Quinn, David I.; Brana, Irene; Moreno, Victor; Borad, Mitesh; Loi, Sherene; Spanggaard, Iben; Park, Haeseong; Ford, James M.; Arnedos, Monica; Stemmer, Salomon M.; de la Fouchardiere, Christelle; Fountzilas, Christos; Zhang, Jie; DiPrimeo, Daniel; Savin, Casey; Selcuklu, S. Duygu; Berger, Michael F.; Eli, Lisa D.; Meric-Bernstam, Funda; Jhaveri, Komal; Solit, David B.; Abou-Alfa, Ghassan K.
errShare
errSave
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
err2022-11-04
err19
errOAAI
errDamrauer, Jeffrey S.; Beckabir, Wolfgang; Klomp, Jeff; Zhou, Mi; Plimack, Elizabeth R.; Galsky, Matthew D.; Grivas, Petros; Hahn, Noah M.; O'Donnell, Peter H.; Iyer, Gopa; Quinn, David, I; Vincent, Benjamin G.; Quale, Diane Zipursky; Wobker, Sara E.; Hoadley, Katherine A.; Kim, William Y.; Milowsky, Matthew, I
errShare
errSave